Abstract: The present invention provides porous microparticles, particularly layer-by-layer microparticles, and methods of use thereof.

Abstract: A recombinant vesicular stomatitis vims (rVSV) carrying one or more genes that encode for the spike protein of SARS-CoV-2 or for both the S protein and the envelope protein of the SARS-CoV-2. Vaccines, regimens and kits having the rVSV are used for the prevention of infections caused by SARS-CoV-2.

Abstract: Vaccine compositions comprising at least one modified immunogen via in vitro glycosylation methods that provide a rational approach for generating glycosylated versions of immunogens via the reducing end of a linear carbohydrate, the reducing end containing an N-acyl-2-amino moiety. Vaccine compositions comprising a plurality of heterologous immunogens associated with a multivalent carrier, wherein at least one immnunogen is glycosylated. Vaccine compositions comprising multivalent carriers and related methods using the vaccine compositions in various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing a bacterial, viral, fungal, or protozoan infection.

Abstract: The present disclosure provides compositions and methods for making and using engineered myeloid cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, wherein the chimeric receptor is encoded by a recombinant nucleic acid.

Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.

Abstract: The present document describes methods for improving likelihood of survival in a stage III-IV ovarian cancer patient, and the use of chemotherapeutic agents (paclitaxel and carboplatin) and therapeutic monoclonal antibodies (oregovomab and bevacizumab) combinations, for inhibiting stage III-IV ovarian cancer tumor growth in a patient. This combination of chemotherapeutic agents and therapeutic monoclonal antibodies is administered according to specific schedules involving 6 cycles of chemotherapy where in each cycle the patient is administered paclitaxel, carboplatin and bevacizumab on the same day, antibody mAb-B43.13 (oregovomab) concurrently during cycles 1, 3, and 5 of the 6 cycles of chemotherapy, and a final dose of monoclonal antibody mAb-B43.13 without concurrent chemotherapy about 10 to about 14 weeks after cycle 5 of the 6 cycles of chemotherapy.

Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.

Abstract: An engineered transcriptional modulator (ETM) comprising: (a) at least one epigenetic effector domain; operably linked to (b) an endonuclease.

Abstract: The present disclosure generally relates to, inter alia, chimeric antigen receptors (CARs) that contain an intracellular signaling domain without an immune receptor tyrosine based activation motif (ITAM). The disclosure also provides compositions and methods useful for producing such molecules, as well as methods for the detection and treatment of diseases, such as cancer.

Abstract: A modified immune effector cell may be one in which the functions of a T cell antigen receptor (TCR) and major histocompatibility complexes (MHCI, MHCII) in the modified immune effector cell are inhibited in a T cell. Such a modified immune effector cell may include a chimeric antigen receptor (CAR) targeting GD2. Such a modified immune effector cell may knock out TCR and HLA-A genes expressed by the cell while recognizing surface antigens of tumor cells, so that multiple effects of improving the anti-tumor effect of CAR-T cells, prolonging the survival time of the cells, and reducing the immune rejection response caused by allogeneic cell therapy may be reduced.

Abstract: Disclosed are off-the-shelf immune effector cells that are engineered to express anti-CD3 antibodies disclosed herein that are configured to autoactivate the immune effector cells, thereby decreasing expression of T cell receptors (e.g. TCR??) that could result in GVHD. Also disclosed are methods for modifying donor immune effector cells to make them suitable for off-the-shelf treatment of allogeneic subjects. These methods involve engineering the cells to express an anti-CD3 antibody configured to activate the cells. In some embodiments, the antibody is a bi-specific antibody that binds the CD3 complex on the immune effector cells. In other embodiments, the antibody is a membrane bound anti-CD3 antibody that autoactivates the immune effector cell.

Abstract: Compositions and methods for reducing MHC class II protein expression in a cell comprising genetically modifying CIITA for use e.g., in adoptive cell transfer therapies.

Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg/kg to 18 mg/kg, preferably 8 to 12 mg/kg, more preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases.

Abstract: Disclosed herein are identified compound fragments, compounds and their pharmaceutically acceptable salts, isotopes or solvates, useful as antiviral drug and/or as a hepatic-targeted drug, such as for the treatment of HBV, HDV and/or HIV. Formula (I).

Abstract: This invention is directed to substituted a methacrylamide compounds as targeted covalent protein binders and uses thereof.

Abstract: The present invention provides a prodrug compound, a preparation method, and the use thereof. In particular, the present invention provides a compound as represented by formula (I), a preparation method, and the use thereof as a prodrug for preparing topical formulations.

Abstract: This invention relates to methods and compositions useful for treatment of subjects with dry age-related macular degeneration or geographic atrophy secondary to dry age-related macular degeneration. The methods involve administration of a pharmaceutical composition comprising an anti-C5 agent ARC1905, which comprises a C5-specific aptamer conjugated to a polyethylene glycol moiety via a linker, in an amount effective for slowing or inhibiting loss of low luminance visual acuity in the subject. The aptamer consists of the sequence fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUfUAfCf CfUmGfCmG-3T, wherein fC and fU=2? fluoro nucleotides, mG and mA=2?-OMe nucleotides, all other nucleotides are 2?-OH, and 3T indicates an inverted deoxythymidine. Dosages and administration schedules are disclosed.

Abstract: Disclosed herein include novel blood-brain barrier (BBB)-crossing receptors on the BBB interface, targeting peptides and derivatives thereof capable of binding to the novel receptors, and related methods of using the receptors to increase the permeability of the BBB and to deliver an agent to a nervous system (e.g., CNS). In some embodiments, the BBB-crossing receptor is LRP6. Disclosed herein also include recombinant adeno-associated viruses (rAAVs) with increased specificity and transduction efficiency across the BBB and related compositions and methods of treating various diseases and conditions.

Abstract: The present invention relates to a pharmaceutical composition, for treating glioblastoma, comprising a nucleic acid complex as an active ingredient and, more particularly, to a pharmaceutical composition, for preventing or treating glioblastoma, comprising a nucleic acid complex having complementarily bound: a bioactive peptide nucleic acid having a sequence binding to TGF-?2 gene; and a carrier peptide nucleic acid. The nucleic acid complex according to the present invention has excellent cell permeability and intracellular activity and can effectively inhibit the expression of TGF-?2 gene and the hypostatic gene thereof, and thus is useful in preventing or treating glioblastoma.

Abstract: Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.

Abstract: The present disclosure relates to 2,6-dichlorophenylester compounds. Also disclosed are methods for using the same for the preparation of certain conjugates.

Abstract: The present disclosure is directed to engineered nanoparticles/liposomes that inhibit enveloped viruses and methods for use thereof.

Abstract: An exine-construct that can be coloured and used as a protection and/or delivery and/or removal vehicle for an active substance, or as an antioxidant. It can be used in a method of surgery, therapy, prevention or diagnosis. The invention provides an exine-construct comprising of exine shells together with an active substance; and a method for preparing the exine-construct by isolating exine shells from a naturally occurring spore and suitably attaching them together.

Abstract: The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

Abstract: The present disclosure relates to a method for treating a cancer and/or cancer metastasis in a subject comprising administering to the subject irinotecan loaded in a mesoporous silica nanoparticle. The present disclosure also provides a conjugate comprising an agent loaded in a mesoporous silica nanoparticle (MSN) defining at least one pore and having at least one functional group on a sidewall of the at least one pore.

Abstract: The present invention provides an artificial TRAP-cage decorated with particular molecules (proteins, peptides, small molecules, nucleic acids) on the exterior.

Abstract: The disclosure relates, in some aspects, to compositions and methods for enhanced delivery of a transgene to the central nervous system (CNS) of a subject. In some embodiments, the transgene is delivered by recombinant AAV (rAAV). In some embodiments, the method of enhancing transgene delivery comprises administering a blood brain barrier (BBB)-crossing molecule (e.g., K16ApoE) and an rAAV comprising a transgene to a subject.

Abstract: The invention relates to gene therapies using viral vectors. The invention provides, for the first time, packaging cells that comprise enhanced Fc receptor expression (e.g. CD16, CD32, or CD64) to generate gene therapy viruses that evade antibody-dependent inactivation (ADI) or complement-dependent inactivation (CDI). The invention also provides gene therapy viruses with the enhanced Fc receptors displayed on their viral envelope.

Abstract: The present invention relates to a nucleic acid molecule for an allele-specific editing of the ELANE gene, a vector comprising said nucleic acid molecule, a composition comprising said nucleic acid molecule or vector, a method in vitro for an allele-specific editing the ELENE gene in biological material including genetic material encoding said ELENE gene, and to a method for the prophylaxis and/or treatment and/or examination of a disease in a living being.

Abstract: The present disclosure is related to compositions and methods useful in treating heart conditions. The disclosed compositions and methods are based on gene therapies comprising a recombinant AAV vector for delivering two or more transgenes into the heart of a subject, wherein the transgenes encode an S100A1 protein and a cardiac Apoptosis Repressor with caspase recruitment Domain (cARC) apoptotic inhibitor, respectively. In various embodiments, the compositions and methods disclosed herein comprise vectors comprising S100A1 and/or cARC cDNA sequences that are codon-optimized for expression in humans. In various embodiments, the compositions and methods disclosed herein comprise vectors with improved packaging efficiencies. In some aspects, targeting multiple sources of one or more heart conditions can provide synergistic benefits during treatment.

Abstract: The present disclosure provides constructs comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a clarin 1 protein. Exemplary constructs include AAV constructs. Also provided are methods of using disclosed constructs for the treatment of hearing loss and/or deafness. Also provided are methods of using disclosed constructs for the treatment of vision loss.

Abstract: The present invention involves nucleic acid vectors (e.g., circular DNA vectors) and compositions thereof. Also provided herein are methods of administering nucleic acid vectors (e.g., circular DNA vectors) and compositions thereof, e.g., in combination with pulsed electric field therapy.

Abstract: The invention relates to a nanostructured delivery system comprising at least one polymer and/or at least one lipid and at least one polymethine dye, for use in treating a subject suffering from an adenocarcinoma comprising adenocarcinoma cells with a gene expression alteration in one or more SLCO genes. Therein, the at least one polymethine dye mediates targeted transport of the nanostructured delivery system into said adenocarcinoma cells. The invention relates further to a pharmaceutical composition comprising the nanostructured delivery system. The invention also relates to a method for targeted transport into neoplastic tissue using the nanostructured delivery system and to a use of the nanostructured delivery system or of the pharmaceutical composition of the invention for detection by fluorescence based on the accumulation of said system or composition in neoplastic tissues or cells.

Abstract: An object is to provide an X-ray contrast agent that is retained in a blood vessel for a predetermined time and then excreted out of the body. The object can be solved by a complex containing a metal nanoparticle and a protein, wherein a metal nanoparticle part in the complex has an average particle size of 1 nm or greater and 5.5 nm or less.

Abstract: Disclosed are a multi-modality molecular imaging probe, and a preparation method and use thereof. The multi-modality molecular imaging probe has an ABA structure, with a magnetic functional unit of a gadolinium complex at the center, and two identical phosphorescent functional units of an iridium complex, which are reasonably integrated into the same one complex molecule. The multi-modality molecular imaging probe simultaneously introduces two optical functional units of the iridium complex and one magnetic functional unit of a gadolinium chelate in the same one complex molecule, which exhibits magnetic-optical dual functional properties. It therefore could be used to prepare both a contrast agent for magnetic resonance imaging and an optical probe for optical imaging.

Abstract: A gadolinium chelate, a preparation method therefor, and an application thereof. The gadolinium chelate is a complex formed by chelation of gadolinium ions and macromolecules. The macromolecules comprise any one of or a copolymer or mixture of two or more of carboxylic acid-containing high-molecular polymers, amino-containing high-molecular polymers, hydroxyl-containing high-molecular polymers, polyester high-molecular polymers, polyether high-molecular polymers, polyamide high-molecular polymers, proteins, polypeptides, and polysaccharides. The gadolinium ions and the macromolecules form the gadolinium chelate by means of chelation. The gadolinium chelate is a water-soluble macromolecular drug, can improve a longitudinal relaxation rate r1 and reduce a ratio of r2/r1, has good water-solubility and high stability, and meanwhile, can exhibit a good imaging effect in a short period of time and shorten an MRI time.

Abstract: A radioactively labeled ligand for a fibroblast activation protein-alpha imaging agent and a preparation method therefor are provided. The radioactively labeled ligand for the fibroblast activation protein-alpha imaging agent has structural formal (I). The compound has a good 68Ga labeling property, a high stability and a good affinity for FAP tumors. The radioactively labeled ligand for 68Ga-labeled FAPi can be used as a tumor positron imaging agent.

Abstract: The invention relates to a targeting system with improved uptake, the use thereof as a medicament, such as for cancers, to a dosage comprising the targeting system, the use thereof in therapy, the use thereof in treatment, and the use thereof in diagnosis or imaging. In particular the invention relates to systems targeting necrotic cells.

Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.

Abstract: Methods of treatment for conditions, e.g., cancer, using a cold FGFR3-targeting molecule and a radioimmunoconjugate comprising a chelating moiety or a metal complex thereof, a linker, and an FGFR3 targeting moiety.

Abstract: Some embodiments relate to imageable radioisotopic microspheres. In some embodiments, the imageable microspheres are radiolabeled with imageable radioisotopes. In some embodiments, the imageable radioisotope is directly coupled to a surface of a substrate of the microsphere. In some embodiments, the imageable microspheres can be used as surrogate particles to predict the distribution of therapeutic microspheres comprising radiotherapeutic isotopes.

Abstract: A cap configured to engage different types of female connectors includes a housing having a closed bottom, an open top, and a sidewall extending between the top and the bottom with threads on an inner surface of the sidewall. The cap also includes a sleeve disposed in the housing with threads engaged to the threads of the housing configured to rotate relative to the housing, thereby moving the sleeve through the housing, and a gripper disposed at least partially in the sleeve having at least one flexible leg pressed radially inward by the sleeve as the sleeve moves through the housing. The cap also includes an absorbent support disposed in the gripper configured to clean and/or disinfect portions of the female connector.

Abstract: A cap configured to engage a male connector and a female connector includes a first housing for the female connector having a closed bottom, an open top, and a sidewall extending between the bottom and the top, and a first absorbent support disposed in the first housing configured to contact portions of the female connector. The cap also includes a removable second housing for the male connector disposed in the first housing. The second housing includes a bottom, a top, and a sidewall extending between the bottom and the top with an outer surface of the sidewall of the second housing engaged to an inner surface of the sidewall of the first housing. The cap also includes a second absorbent support disposed in the removable second housing configured to contact portions of the male connector.

Abstract: Disclosed herein are methods for pasteurizing or sterilizing architectural coating compositions using elevated heat dynamically with or without pressure.

Abstract: An ultraviolet sterilization lamp structure relates to the technical field of disinfection and sterilization, comprising: a lamp board; an ultraviolet lamp connected to the lamp board, a light source convex lens arranged on a positive side of the ultraviolet lamp, and a strip-shaped convex lens laterally arranged on an outer side of the light source convex lens. With the above technical solution, the ultraviolet light is optically zoomed twice through the light source convex lens and the strip-shaped convex lens to achieve an effect of vertical concentration and horizontal diffusion, ensuring that the horizontal angle of the irradiation is large and the vertical angle is small, avoiding the exposure to the personnel activity area, so that the personnel do not have to leave the room when sterilizing, thereby embodying the coexistence of man and machine and improving the immediacy and practicality of ultraviolet air sterilizing.

Abstract: The present invention relates to a control technology of an electronic household trash container, in particular, a circuit control method of induction trash can with cold cathode ultraviolet lamp deodorization, which includes steps of setting a working cycle and a turn-off cycle of a ultraviolet sterilization and deodorization circuit, setting up an infrared pulse testing circuit to work for a predetermine number of times per second during the working cycle, wherein each working time of the infrared pulse testing circuit is 1 ms˜8 ms.

Abstract: The present invention relates to a disinfecting device, a disinfecting system and a method for control the disinfecting device. The disinfecting device (1) comprising a light bar (10) configured to be mounted to a surface (2) of an indoor space (4), said light bar (10) including at least one light source (100), and at least one optical element (102), configured to shape disinfecting light emitted by the light source(s) (100), such that the light bar (10) is configured to emit disinfecting light in an optical plane (140) extending from a longitudinal axis of the light bar (10); and a slant angle controller (120), configured to, when the light bar (10) is mounted to a surface (2), control a slant angle (S, S2) between the optical plane (140) and the surface (4).

Abstract: The present disclosure relates generally to systems, devices and methods for disinfection of space and equipment. In particular, the present disclosure relates to systems, devices and methods, such as rolling enclosures, which use light sources, such as ultraviolet (UV) light, and more specifically UV-C light, to disinfect larger scale equipment or spaces. Systems and methods of the present disclosure are particularly useful in medical facilities for treating medical equipment or spaces, where the prevalence of pathogens requires frequent disinfecting.

Abstract: A sterilization apparatus includes a housing; a sterilization unit for irradiating, with sterilization light, at least one region to be sterilized; and a driving unit for moving the sterilization unit into and out of the housing via an opening of the housing and rotating the sterilization unit about a rotation axis.